← Guardant Health, Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net loss | ($410k) | ($83.2m) | ($84.3m) | ($67.9m) | ($246.3m) | ($384.8m) | ($654.6m) | ($479.4m) | ($436.4m) | ($416.3m) | — | |
| Depreciation and amortization | $3.7m | $5.2m | $7.1m | $11.4m | $16.1m | $22.3m | $36.0m | $42.9m | $42.4m | $39.7m | $38.5m | |
| Amortization of discount on marketable debt securities | $287k | $359k | ($412k) | ($2.3m) | $4.0m | $12.8m | $4.6m | ($13.6m) | ($6.8m) | ($5.9m) | — | |
| Amortization of Intangibles | $60 | — | — | — | — | — | — | — | — | — | — | |
| Stock-based compensation | $2.0m | $3.7m | $6.9m | $17.0m | $144.1m | $151.4m | $94.7m | $90.8m | $140.4m | $166.2m | $191.3m | |
| Impairment of non-marketable equity securities and other related assets | — | — | — | — | $0 | $0 | $5.3m | $29.1m | $0 | $18.6m | — | |
| Accounts receivable, net | ($9k) | ($9.3m) | ($22.9m) | ($7.4m) | ($5.5m) | ($44.4m) | $375k | $8.4m | ($21.4m) | ($28.2m) | ($13.7m) | |
| Inventory, net | $8k | ($4.5m) | ($1.8m) | ($6.0m) | ($7.5m) | ($8.0m) | ($20.9m) | ($10.3m) | ($9.1m) | ($14.8m) | ($21.4m) | |
| Accounts payable and accrued liabilities | — | — | — | — | $505k | $34.8m | $60.3m | $88.6m | ($2.8m) | $52.7m | — | |
| Purchases of property and equipment included in accounts payable and accrued liabilities | — | — | — | — | — | $8.9m | $8.3m | $5.3m | $3.8m | $4.1m | ($55.5m) | |
| Increase (Decrease) in accounts payable and accrued expenses | $129k | — | — | — | — | — | — | — | — | — | — | |
| Deferred revenue | $1.7m | $1.2m | $13.0m | ($3.9m) | ($3.7m) | $2.8m | $9.9m | $1.7m | $18.7m | $19.5m | — | |
| Other | — | — | ($13k) | $0 | $7.2m | $47k | $21k | $6.0m | ($153k) | $3.6m | — | |
| Prepaid expenses and other current assets, net | ($610k) | $30k | ($3.7m) | ($6.2m) | ($6.1m) | ($35.8m) | $20.4m | ($4.3m) | ($7.7m) | ($6.4m) | — | |
| Other assets, net | $12k | ($883k) | ($451k) | ($2.9m) | ($19.3m) | ($4.2m) | $11.7m | $1.3m | ($2.4m) | $212k | — | |
| (Increase) Decrease in prepaid expenses and other current assets | $643 | — | — | — | — | — | — | — | — | — | — | |
| Net cash used in operating activities | ($39k) |
($72.2m)
-183877.28%
|
($72.2m)
+0.07%
|
($47.1m)
+34.70%
|
($103.9m)
-120.49%
|
($209.0m)
-101.12%
|
($309.5m)
-48.06%
|
($325.0m)
-5.01%
|
($239.9m)
+26.19%
|
($184.8m)
+22.97%
|
($185.2m)
-0.23%
|
|
| Net Cash from Operating Activities | $2k |
($72.2m)
-3852633.33%
|
($72.2m)
+0.07%
|
($47.1m)
+34.70%
|
($103.9m)
-120.49%
|
($209.0m)
-101.12%
|
($309.5m)
-48.06%
|
($325.0m)
-5.01%
|
($239.9m)
+26.19%
|
($184.8m)
+22.97%
|
($185.2m)
-0.23%
|
|
| Purchases of property and equipment | $1.8m | ($6.7m) | ($20.2m) | ($18.7m) | ($36.2m) | ($75.0m) | ($77.5m) | ($20.5m) | ($35.1m) | ($48.3m) | ($55.5m) | |
| Interest income received on marketable debt securities | — | — | — | — | — | — | — | $0 | $0 | $7.7m | — | |
| Purchases of marketable debt securities | — | — | — | — | — | ($900.8m) | ($303.8m) | ($629.9m) | ($307.3m) | ($818.2m) | — | |
| Maturities of marketable debt securities | — | — | — | — | — | $952.1m | $555.0m | $1.5b | $35.0m | $307.3m | — | |
| Net cash (used in) provided by investing activities | $250 | ($170.4m) | ($153.0m) | ($317.6m) | ($617.1m) | ($63.2m) | $149.8m | $840.2m | ($261.3m) | ($627.2m) | — | |
| Proceeds from borrowings on convertible senior notes | — | — | $0 | $0 | $1.1b | $0 | $0 | $0 | $0 | $402.5m | — | |
| Payment of debt issuance costs | — | — | — | $0 | $0 | ($784k) | $0 | $0 | $0 | ($24.6m) | — | |
| Proceeds from Debt Issuance | $128k | — | — | — | — | — | — | — | — | — | — | |
| Proceeds from issuance of common stock under employee stock purchase plan | — | $0 | $0 | $6.4m | $7.1m | $9.8m | $9.3m | $10.2m | $11.7m | $13.6m | $345.0m | |
| Proceeds from issuance of common stock upon exercise of stock options | $266k | $753k | $3.1m | $11.6m | $9.5m | $8.1m | $2.6m | $405k | $3.1m | $19.2m | $345.0m | |
| Employee taxes paid related to net share settlement of restricted stock units | $14k | $26k | $0 | $0 | ($3.4m) | ($83.8m) | ($7.9m) | ($11.2m) | ($15.7m) | ($30.5m) | — | |
| Net cash provided by (used in) financing activities | $58k |
$281.7m
+489736.52%
|
$293.2m
+4.08%
|
$367.3m
+25.29%
|
$1.4b
+283.96%
|
($66.8m)
-104.74%
|
($189.1m)
-182.97%
|
$477.4m
+352.46%
|
($996k)
-100.21%
|
$671.1m
+67482.83%
|
$737.8m
+9.93%
|
|
| Net (decrease) increase in cash, cash equivalents and restricted cash | $29.3m | $39.0m | $67.9m | $2.7m | $689.7m | ($340.7m) | ($350.3m) | $991.7m | ($503.9m) | ($140.3m) | — | |
| Cash, cash equivalents and restricted cash – Beginning of period | $33.6m | $72.6m | $140.5m | $143.2m | $833.0m | $492.3m | $141.9m | $1.1b | $629.8m | $489.4m | — | |
| Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash | — | $0 | $0 | $84k | $455k | ($1.7m) | ($1.6m) | ($911k) | ($1.8m) | $491k | — | |
| Restricted cash – included in restricted cash | — | — | — | — | — | $86k | $301k | $150k | $104.2m | $111.2m | — | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Operating lease costs | — | — | $0 | $4.4m | $5.6m | $24.7m | $28.6m | $29.7m | $31.1m | $33.6m | — | |
| Gain on extinguishment of convertible notes | $0 | $5.1m | $0 | $0 | — | — | — | $0 | $0 | ($13.7m) | — | |
| Unrealized and realized losses (gains) on marketable equity securities | — | — | — | — | — | — | $7.8m | ($79.7m) | $44.4m | $0 | — | |
| Other legal liabilities | — | — | — | — | — | — | $0 | $83.4m | $0 | $0 | — | |
| Operating lease liabilities | — | — | $0 | ($1.2m) | ($6.0m) | $14.2m | ($20.2m) | ($31.5m) | ($36.1m) | ($37.5m) | — | |
| Sales of marketable equity securities and other related assets | — | — | — | — | — | — | $0 | $1.5m | $53.6m | $0 | — | |
| Purchases of non-marketable equity securities and other related assets | — | — | — | $0 | $0 | ($39.4m) | ($24.0m) | ($5.6m) | ($7.5m) | ($9.0m) | — | |
| Acquisition of business, net of cash acquired | — | $0 | $0 | ($7.3m) | $0 | $0 | — | $0 | $0 | ($59.0m) | — | |
| Repurchase of treasury stock | $100k | ($7.2m) | ($172k) | $0 | $0 | — | — | $0 | $0 | ($45.0m) | — | |
| Proceeds from reissuance of treasury stock | — | — | — | — | — | — | — | $0 | $0 | $87.9m | — | |
| Proceeds from equity offerings | — | $0 | $254.0m | $350.4m | $355.7m | $0 | $0 | $493.1m | $0 | $257.1m | — | |
| Payment of equity offering costs | $0 | $0 | ($4.4m) | ($723k) | ($1.1m) | $0 | $0 | ($21.1m) | $0 | ($17.7m) | — | |
| Proceeds from unwinding of convertible note hedges | — | — | — | — | — | — | — | $0 | $0 | $5.0m | — | |
| Cash paid for interest | $2.2m | $1.3m | $1.3m | $1.2m | $0 | $0 | — | $0 | $0 | $3.8m | — | |
| Cash paid for income taxes | $14k | $26k | $102k | $298k | $331k | $393k | $1.3m | $2.0m | $1.0m | $869k | — | |
| Operating lease liabilities arising from obtaining right-of-use assets | — | $0 | $0 | $16.7m | $13.1m | $171.4m | $4.1m | $5.0m | $7.9m | $41.2m | — | |
| Cash and cash equivalents | $2k | — | — | — | — | $492.2m | $141.6m | $1.1b | $525.5m | $378.2m | $735.5m | |
| Interest Expense | $240k | — | — | — | — | — | — | — | — | — | — | |
| Total adjustments | $371k | — | — | — | — | — | — | — | — | — | — | |
| Increase in due from affilliate | $250 | — | — | — | — | — | — | — | — | — | — | |
| Payments on notes and loans payable | ($71k) | — | — | — | — | — | — | — | — | — | — | |
| Net Change in Cash | $18k | — | — | — | — | — | — | — | — | — | — | |
| CASH - END OF YEAR | $21k | |||||||||||
| Beneficial conversion feature | $295k | — | — | — | — | — | — | — | — | — | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.